Orexo AB (publ) (OM: ORX)
Health Care · Pharmaceuticals · SE
Skr13.30
-4.04% today · -33.4% 1Y
Orexo AB (publ) (OM: ORX) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $51.11M and employs 61 people.
Over the last twelve months the share price has lost 33.4%, trading between 13.50 and 43.40.
Tweenvest scores Orexo AB (publ) across four factors: quality 61/100, value 29/100, growth 0/100. Its strongest factor is quality.
ORX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $51.11M
- Revenue (TTM)
- $1.71M
- P/E
- —
- EPS
- 13.24
- Dividend yield
- —
- Beta (5Y)
- 0.85
- 52-week high
- Skr43.40
- 52-week low
- Skr13.50
- Avg volume (3M)
- —
- Shares outstanding
- 34.92M
- Employees
- 61
- Next earnings
- —
About Orexo AB (publ)
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and OX-MPI for the treatment of endometriosis. Its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
- ISIN
- SE0000736415
- Founded
- 1994
- Listed since
- Nov 9, 2005
- Exchange
- OMX Nordic Exchange Stockholm
- Currency
- SEK
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,233.66 | 0.00% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.18 | +0.01% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.24 | -0.13% |
| Roche Holding AGSWX: ROP | $371.62B | CHF370.90 | -0.78% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £123.18 | -1.27% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.52 | -0.18% |
Figures last refreshed Aug 18, 2026.